Drugs / AVANZ Cupressus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02069535 | Apr → Nov 2014 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVANZ Cupressus | “An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy” NCT02069535 ↗ |
| Known as | AVANZ Cupressus arizonica | “This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by...” NCT02069535 ↗ |